Thus, combined therapy of IDO1 inhibitor and anti-CTLA-4 treatment emerges as a rational approach to improve the checkpoint-based treatments for the resistant types of HCC (Figure 2) [153]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.